YIH
BDTX icon

Y-Intercept (HK)’s Black Diamond Therapeutics BDTX Stock Holding History

Y-Intercept (HK)’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,521
Closed -$36K – 1576
2025
Q2 		$36K Buy
+14,521
New +$28K ﹤0.01% 1574
2024
Q2 		– Sell
-27,586
Closed -$140K – 1400
2024
Q1 		$140K Buy
27,586
+8,017
+41% +$32.3K 0.01% 1219
2023
Q4 		$55K Buy
+19,569
New +$45.9K 0.01% 1152

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Y-Intercept (HK)'s BDTX Position: Q3 2025 in Review

Y-Intercept (HK) sold out of Black Diamond Therapeutics (BDTX) in Q3 2025, closing a stake of 14,521 shares — an estimated $36K sold.

Y-Intercept (HK) first reported a position in BDTX in Q4 2023 and held it in 3 quarters. The position peaked at $140K in Q1 2024. 91 funds tracked by Wall St. Rank hold BDTX as of Q3 2025.

  • Y-Intercept (HK) reported no remaining Black Diamond Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Y-Intercept (HK) sold 14,521 Black Diamond Therapeutics shares in Q3 2025, an estimated $36K.
  • Y-Intercept (HK) first reported a position in Black Diamond Therapeutics in Q4 2023 and held it in 3 quarters.
  • Y-Intercept (HK)'s Black Diamond Therapeutics position peaked at $140K in Q1 2024.
  • 91 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2025.

Based on Y-Intercept (HK)'s 13F filing for Q3 2025, filed 31 Oct 2025.